Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for human vaccine development.
Although harmless in humans, parainfluenza virus 5, or PIV5, is thought to contribute to upper respiratory infections in dogs, and it is a common target for canine vaccines designed to prevent kennel cough. In a paper published recently in PLOS ONE, researchers describe how this virus could be used in humans to protect against diseases that have eluded vaccine efforts for decades.
"We can use this virus as a vector for all kinds of pathogens that are difficult to vaccinate against," said Biao He, the study's principal investigator and professor of infectious diseases in UGA's College of Veterinary Medicine. "We have developed a very strong H5N1 flu vaccine with this technique, but we are also working on vaccines for HIV, tuberculosis and malaria."
PIV5 does not cause disease in humans, as our immune system is able to recognize and destroy it. By placing antigens from other viruses or parasites inside PIV5, it effectively becomes a delivery vehicle that exposes the human immune system to important pathogens and allows it to create the antibodies that will protect against future infection.
This approach not only ensures full exposure to the vaccine but also is much safer because it does not require the use of attenuated, or weakened, pathogens. For example, an HIV vaccine delivered by PIV5 would contain only those parts of the HIV virus necessary to create immunity, making it impossible to contract the disease from the vaccine.
"Safety is always our number one concern," said He, who is also a Georgia Research Alliance distinguished investigator and member of the Faculty of Infectious Diseases. "PIV5 makes it much easier to vaccinate without having to use live pathogens."
Using viruses as a delivery mechanism for vaccines is not a new technique, but previous efforts have been fraught with difficulty. If humans or animals already possess a strong immunity to the virus used for delivery, the vaccine is unlikely to work, as it will be destroyed by the immune system too quickly.
"Pre-existing immunity to viruses is the main reason most of these vaccines fail," He said.
But in this latest study, He and his colleagues demonstrate that immunity to PIV5 does not limit its effectiveness as a vaccine delivery mechanism, even though many animals–including humans– already carry antibodies against it.
In their experiments, the researchers found that a single dose inoculation using PIV5 protected mice from the influenza strain that causes seasonal flu. Another single dose experimental vaccine also protected mice from the highly pathogenic and deadly H5N1 virus commonly known as bird flu.
This recent work is a culmination of more than fifteen years of research and experimentation with the PIV5 virus, and He has confidence that it will serve as an excellent foundation for vaccines to treat diseases in both animals and humans.
"I believe we have the best H5N1 vaccine candidate in existence," He said. "But we have also opened up a big field for a host of new vaccines."
University of Georgia: http://www.uga.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
By dipping live specimens in a chemical concoction, scientists are able to keep them alive in the vacuum conditions normally required for field emission scanning electron microscopy.
Astra Zeneca announces a research programme to develop a generation of medicines to treat the genetic causes of many debilitating diseases.
When patients with Parkinson's disease received an injection described as an effective drug costing $1,500 per dose, their motor function improved significantly more than when they got one supposedly costing $100, scientists reported on Wednesday.
New research shows that teenagers' brains aren't fully insulated, so the signals travel slowly when they need to make decisions. Neuroscientist Frances Jensen, who wrote The Teenage Brain, explains.
Researchers would use cohort of 1 million Americans pooled from smaller studies to study disease-gene links, improve personalized medicine
Some people have non-human neighbors of the usual, inspiring kind: Bald eagles and bears, sea lions and salamanders, the sort of creatures found in nature documentaries intoned by deep-voiced narrators who plead on our planet's behalf. But I live in New York City. The star of this show, a charismatic megafauna of my own particular wilderness, is none other than the rat — and what science is teaching us may change how we think of this oft-reviled creature, and maybe even ourselves.
An Oregon company has developed a high-tech process for turning sewage into pure drinking water. Now it's asking the state for permission to give its recycled water to a group of home brewers.
Skull cap of Homo sapiens found in Israeli cave hints at time and place of cross-species mingling
Is there a conscious generosity in how ravens or bats share food, or monkeys or elephants save others, or is it simply the selfish instinct of group survival?
DNA research into early canine remains also raises clues about migration patterns of ancient humans